Bullfrog AI Holdings shares surge 60.00% intraday after securing partnership with top-five global pharmaceutical company to accelerate MDD drug discovery using its bfLEAP platform.

Bullfrog AI Holdings surged 60.00% intraday, as the company announced a commercial agreement with one of the world's top five pharmaceutical firms. Under the deal, the firm will use its proprietary bfLEAP platform to identify and prioritize new drug targets for major depressive disorder (MDD), accelerating the client's drug discovery and clinical development. The agreement grants the client exclusive rights to the candidate targets and secures access to the MDD market, which exceeded $8 billion in 2025 and is projected to surpass $11 billion by 2032.